William J. Valente

William J. Valente

Auto-generated profile, based on publicly available information

William J. Valente

Fred Hutchinson Cancer Research Center, Seattle, WA, USA

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
GZGrace X. Y. Zheng
Grace X. Y. Zheng
JTJessica M. Terry
Jessica M. Terry
PBPhillip Belgrader
Phillip Belgrader
PRPaul Ryvkin
Paul Ryvkin
ZBZachary W. Bent
Zachary W. Bent
JBJason H. Bielas
Jason H. Bielas
Characterizing the transcriptome of individual cells is fundamental to understanding complex biological systems. We describe a droplet-based system that enables 3′ mRNA counting of tens of thousands of single cells per sample. Cell encapsulation, of up to 8 samples at a time, takes place in ∼6 min, with ∼50% cell capture efficiency. To demonstrate the system’s technical performance, we collected transcriptome data from ∼250k single cells across 29 samples. We validated the sensitivity of the system and its ability to detect rare populations using cell lines and synthetic RNAs. We profiled 68k peripheral blood mononuclear cells to demonstrate the system’s ability to characterize large immune populations. Finally, we used sequence variation in the transcriptome data to determine host and donor chimerism at single-cell resolution from bone marrow mononuclear cells isolated from transplant patients.

24 September 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
KPK. G. Paulson
K. G. Paulson
VVV. Voillet
V. Voillet
MMM. S. McAfee
M. S. McAfee
DHD. S. Hunter
D. S. Hunter
FWF. D. Wagener
F. D. Wagener
ACA. G. Chapuis
A. G. Chapuis
Understanding mechanisms of late/acquired cancer immunotherapy resistance is critical to improve outcomes; cellular immunotherapy trials offer a means to probe complex tumor–immune interfaces through defined T cell/antigen interactions. We treated two patients with metastatic Merkel cell carcinoma with autologous Merkel cell polyomavirus specific CD8+ T cells and immune-checkpoint inhibitors. In both cases, dramatic remissions were associated with dense infiltration of activated CD8+s into the regressing tumors. However, late relapses developed at 22 and 18 months, respectively. Here we report single cell RNA sequencing identified dynamic transcriptional suppression of the specific HLA genes presenting the targeted viral epitope in the resistant tumor as a consequence of intense CD8-mediated immunologic pressure; this is distinguished from genetic HLA-loss by its reversibility with drugs. Transcriptional suppression of Class I loci may underlie resistance to other immunotherapies, including checkpoint inhibitors, and have implications for the design of improved immunotherapy treatments.

24 July 2017 in Nature Methods
Verified
Journal Article
Open access
PDF file
JRJohn C Rose
John C Rose
JSJason J Stephany
Jason J Stephany
WVWilliam J Valente
William J Valente
BTBridget M Trevillian
Bridget M Trevillian
HDHa V Dang
Ha V Dang
DFDouglas M Fowler
Douglas M Fowler
A rapidly inducible, autoinhibited SpCas9 and quantitative assessment of double-strand cleavage and indel formation allow insights into Cas9 kinetics in cell lines. We developed a chemically inducible Cas9 (ciCas9) and a droplet digital PCR assay for double-strand breaks (DSB-ddPCR) to investigate the kinetics of Cas9-mediated generation and repair of DSBs in cells. ciCas9 is a rapidly activated, single-component Cas9 variant engineered by replacing the protein's REC2 domain with the BCL-xL protein and fusing an interacting BH3 peptide to the C terminus. ciCas9 can be tunably activated by a compound that disrupts the BCL-xL–BH3 interaction within minutes. DSB-ddPCR demonstrates time-resolved, highly quantitative, and targeted measurement of DSBs. Combining these tools facilitated an unprecedented exploration of the kinetics of Cas9-mediated DNA cleavage and repair. We find that sgRNAs targeting different sites generally induce cleavage within minutes and repair within 1 or 2 h. However, we observe distinct kinetic profiles, even for proximal sites, and this suggests that target sequence and chromatin state modulate cleavage and repair kinetics.

22 August 2016 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
WVWilliam J. Valente
William J. Valente
NENolan G. Ericson
Nolan G. Ericson
ALAlexandra S. Long
Alexandra S. Long
PWPaul A. White
Paul A. White
FMFrancesco Marchetti
Francesco Marchetti
JBJason H. Bielas
Jason H. Bielas
The accumulation of somatic mitochondrial DNA (mtDNA) mutations contributes to the pathogenesis of human disease. Currently, mitochondrial mutations are largely considered results of inaccurate processing of its heavily damaged genome. However, mainly from a lack of methods to monitor mtDNA mutations with sufficient sensitivity and accuracy, a link between mtDNA damage and mutation has not been established. To test the hypothesis that mtDNA-damaging agents induce mtDNA mutations, we exposed MutaTMMouse mice to benzo[a]pyrene (B[a]P) or N-ethyl-N-nitrosourea (ENU), daily for 28 consecutive days, and quantified mtDNA point and deletion mutations in bone marrow and liver using our newly developed Digital Random Mutation Capture (dRMC) and Digital Deletion Detection (3D) assays. Surprisingly, our results demonstrate mutagen treatment did not increase mitochondrial point or deletion mutation frequencies, despite evidence both compounds increase nuclear DNA mutations and demonstrated B[a]P adduct formation in mtDNA. These findings contradict models of mtDNA mutagenesis that assert the elevated rate of mtDNA mutation stems from damage sensitivity and abridged repair capacity. Rather, our results demonstrate induced mtDNA damage does not readily convert into mutation. These findings suggest robust mitochondrial damage responses repress induced mutations after mutagen exposure.

1 May 2009 in Chemical Engineering Science
Verified
Journal Article
Closed access
WVW.J. Valente
W.J. Valente
EPE. Pienaar
E. Pienaar
AFA. Fast
A. Fast
AFA. Fluitt
A. Fluitt
SWS.E. Whitney
S.E. Whitney
HVH.J. Viljoen
H.J. Viljoen